文献速递细菌感染、耐药与抗菌药物艾滋病与性传播感染

西班牙加泰罗尼亚地区生殖支原体大环内酯耐药性:一项为期1年的前瞻性研究

Macrolide resistance in Mycoplasma genitalium in Catalonia, Spain: a 1 year prospective study.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该研究在巴塞罗那邻近地区开展为期1年的前瞻性研究,纳入3540例患者,生殖支原体阳性率为3.7%(132例)。大环内酯耐药率为12.6%,最常见突变为A2058G,且耐药与既往生殖支原体检出史相关(P < 0.001)。仅61.4%患者接受 adequate 初始治疗,42%患者进行治愈检测。

要点

  • 生殖支原体阳性率3.7%,大环内酯耐药率12.6%,最常见突变为A2058G。
  • 耐药与既往生殖支原体检出史显著相关(P < 0.001)。
  • 仅61.4%患者初始治疗 adequate,42%进行治愈检测,建议检测时纳入大环内酯耐药检测。

核心结论

  • 结果支持既往大环内酯使用与耐药菌株产生的关联。
  • 鉴于对所有患者进行治愈检测存在困难,应将大环内酯耐药检测纳入检测项目。

研究设计与样本

  • 为期1年的前瞻性研究,在巴塞罗那邻近地区异质性人群中开展,纳入3540例患者。
  • 对所有送至机构进行性传播疾病检测的标本进行生殖支原体检测,阳性病例收集流行病学和临床数据。
  • 通过23S rDNA测序进行大环内酯相关耐药特征分析。

主要发现

  • 3540例患者中132例(3.7%)生殖支原体阳性。
  • 20.4%的生殖支原体病例同时检出另一种性传播细菌,最常见为沙眼衣原体(11%)。
  • 仅61.4%患者接受针对生殖支原体的 adequate 初始治疗。
  • 42%患者进行治愈检测,10例检测到治疗失败。
  • 大环内酯耐药率为12.6%,最常见突变为A2058G;耐药与既往生殖支原体检出史相关(P < 0.001)。

关键数值与推荐

  • 生殖支原体阳性率:3.7%(132/3540)。
  • 大环内酯耐药率:12.6%。
  • 最常见耐药突变:A2058G。
  • 合并沙眼衣原体感染率:11%。
  • 耐药与既往生殖支原体检出史相关:P < 0.001。

临床怎么用

  • 对生殖支原体感染应关注大环内酯耐药,建议检测时纳入耐药检测。
  • 初始治疗需确保 adequate,并提高治愈检测覆盖率。
  • 既往生殖支原体感染史提示耐药风险升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mycoplasma genitalium is an emergent cause of sexually transmitted disease (STD). The first-line treatment is azithromycin, but macrolide resistance is increasing due to mutations in the 23S rRNA gene. OBJECTIVES: To determine the rates of M. genitalium infection and macrolide resistance in an area adjacent to Barcelona. METHODS: This 1 year prospective study was performed in a heterogenous population that included both low- and high-risk patients. M. genitalium was detected in all specimens sent to our institution for STD detection. Epidemiological and relevant clinical data were collected in the positive cases. Characterization of macrolide-associated resistance was performed by 23S rDNA sequencing. RESULTS: Of the 3540 patients included, 132 (3.7%) were positive for M. genitalium. Another sexually transmitted bacteria was detected in 20.4% of the M. genitalium cases, and Chlamydia trachomatis (11%) was the most frequently co-detected microorganism. Only 61.4% of patients received an adequate initial treatment against M. genitalium. The test of cure (TOC) was performed in 42% of patients, and therapeutic failure was detected in 10 cases. The rate of macrolide resistance was 12.6% and the most prevalent mutation was A2058G. There was an association between macrolide resistance and a previous history of M. genitalium detection (P < 0.001). CONCLUSIONS: Our results support the contribution of the previous use of macrolides in resistant strains. Given the difficulties in performing TOC in all patients, the inclusion of macrolide resistance in the detection test should be mandatory.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Lucena Nemirosky J, Espelt R, López Grado E, et al. Macrolide resistance in Mycoplasma genitalium in Catalonia, Spain: a 1 year prospective study. J Antimicrob Chemother. 2021. PMID: 34278431. doi:10.1093/jac/dkab224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。